Aragen’s formulation manufacturing facility to begin operations in 2023

Aragen is set to open their new manufacturing facility at their Mallapur campus in Hyderabad, India in January 2023, enhancing the company’s ability to provide scaled manufacturing solutions and clinical supplies to their customers.

As a research, development, and manufacturing solutions partner, Aragen aims to offer a range of solutions throughout the drug development process for small and large molecule programs. With eight facilities across the globe, Aragen aims to scale and service large pharmaceutical, biotech, agrochemical, and animal health industries. The new facility will offer manufacturing suites purposely built to support wet granulation, roller compaction, and fluid bed coating, amongst other cGMP manufacturing needs. 

A wide range of dosage forms will be covered, including oral solids, liquids, topicals, and films, as well as manufacturing technologies to achieve granulation, film coating, spray drying, and tableting. The new facility will enhance Aragen’s New Chemical Entity (NCE) early-stage development capabilities, providing their customers the ability to discover and develop drugs with greater flexibility in multiple dosage forms. Flexible batch sizes can range from 1000–100,000 units with improved process technologies. 

Manni Kantipudi, CEO at Aragen Life Sciences, commented on the development: “Aragen is investing in expanding capacities, extending capabilities, and widening its geographic footprint to meet the needs of the global biopharma industry. We understand that our customers rely on our expertise, track record, and solution offerings. With this facility, we will consolidate our drug product development solution offerings and strengthen our position as a one-stop shop for all their needs – transforming ideas into solutions for better health.” 

Chief Commercial Officer Ramesh Subramanian added: “The formulation manufacturing facility in Hyderabad is a significant development for us. The new capacity will allow us to address the increasing interest from our customers for integrated development solutions. It also fits in well with our stated vision of becoming the ‘R&D partner of choice’ for our customers. With this drug product facility and our recent acquisition of Intox to provide safety assessment services, we can now assist our partners from HIT through Clinical Proof of Concept-Phase IIB, accelerating their journey towards impacting patients.” 

Source: Aragen to operationalize cutting-edge formulation manufacturing facility in Hyderabad, India - Aragen Life Sciences